HIGHLIGHTS
- who: Marina Boziki and collaborators from the Multiple Sclerosis Center of the, nd Neurological University Department, School of Medicine, Thessaloniki, Greece have published the research: Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response, in the Journal: Cells 2022, 1959 of /2022/
- what: This study aims to assess the efficacy of ocrelizumab in a cohort of patients with active progressive MS and to dissect the clinical, radiological and laboratory attributes of treatment response. In the present study, ocrelizumab response was linked neither to low IL-6 serum . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.